Navigation Links
Misonix Announces New Distribution Agreement For Panama
Date:4/24/2012

FARMINGDALE, N.Y., April 24, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spine surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, has entered into a new, three year, exclusive distribution agreement with Neuro Dynamics S.A. for the distribution of the SonaStar® Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone Cutter.  The agreement provides Neuro Dynamics with the right to sell throughout Panama.  Included in the agreement are annual minimum purchase requirements.  Product training is complete and open market sales have commenced.

Neuro Dynamics is well established in the fields of spine surgery and neurosurgery with a well-earned reputation for successfully introducing state-of-the-art technology to the market in Panama.  Their commitment to product support and education is consistent with the core values of Misonix.

The SonaStar is used by neurosurgeons and general surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

"We are very pleased to add Neuro Dynamics to our rapidly expanding, broad-based Latin American distribution team.  Their reputation for successfully introducing new technologies to the Panamanian healthcare community is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.  "We are particularly pleased that they will be selling two of our key products throughout Panama."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic surgical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contacts Misonix Contact:

Lytham Partners, LLCRichard Zaremba

Robert Blum, Joe Dorame, Joe Diaz631-694-9555

602-889-9700invest@misonix.com

mson@lythampartners.com 


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Announces New Distribution Agreement for Malaysia and Singapore
2. Misonix Reports a 29% and 24% Increase in Revenue for the Second Quarter and Six Months Fiscal 2012 Financial Results
3. Misonix, Inc. Retains Lytham Partners for Investor Relations
4. Misonix Announces New Distribution Agreement for Thailand
5. Misonix Announces New Distribution Agreement for Algeria
6. Misonix Announces New Distribution Agreement for India
7. Misonix Reports a 14.8% Increase in Revenue for the First Quarter Fiscal 2012 Financial Results
8. Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 at 4:30 p.m. Eastern
9. Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
10. Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care
11. Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, ... ... at US$ 7,167.6 Mn in 2015, and is expected to ... of 5.6% from 2016 to 2024. The ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... As President ... are preparing for how his administration could impact the employee benefits industry. James ... changes are most likely to make it through Congress. His discussion will focus ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... on contracted partners to help with process innovation in drug formulation and manufacturing. ... experience along with state-of-the-art analytical equipment in support of their development and manufacturing ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider of ... management module. Using this new feature, sleep physicians can now predict the likelihood ... positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The ...
(Date:4/24/2017)... ... ... Emmanuel College is introducing enhancements to its RN-to-BSN Degree Program ... of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a Bachelor of ... little as $14,528. These changes will enable nurses to complete their degree in a ...
(Date:4/24/2017)... , ... April 24, 2017 , ... As part of ... today to honor the victims of the Holocaust and Nazi persecution, Center for ... Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland next week. ...
Breaking Medicine News(10 mins):